‘New Hanmi’ Organizational Restructuring Outline... Sales-Centered ‘5+1’ System

The 'New Hanmi' led by brothers Lim Jong-yoon and Jong-hoon, who succeeded in securing management rights of Hanmi Pharmaceutical Group, is taking shape. When President Lim Jong-yoon joins Hanmi Pharmaceutical, the group's core affiliate, an organizational restructuring and personnel changes centered on sales operations are expected to be implemented.

According to industry sources on the 7th, Hanmi Pharmaceutical is set to carry out an organizational restructuring to change into a '5 business divisions and 1 research center' structure. This so-called '5+1 unit' system is reported to maintain the existing framework of Hanmi Pharmaceutical while focusing on domestic and international sales operations.

The 'New Hanmi Pharmaceutical' is expected to consist of five business divisions?Manufacturing Division, Domestic Business Division, Marketing Division, Development Division, Overseas Business Division?and a research center. The existing headquarters system will be changed to a business division system, and a marketing division has been newly established to promote aggressive sales activities. The focus is evaluated to be on stability rather than radical innovation.

Key personnel are also expected to be reassigned. Park Jae-hyun, the current CEO of Hanmi Pharmaceutical, is anticipated to lead the Manufacturing Division. Park Myung-hee, Executive Director and head of the Domestic Business Headquarters, is expected to take charge of the newly established Marketing Division, while Lim Jong-ho, Executive Director of Corporate Social Responsibility, is likely to lead the Overseas Business Division. The Development Division will continue to be led by Kim Na-young, head of the New Product Development Headquarters. Lim Joo-hyun, Vice Chairman of Hanmi Pharmaceutical, will effectively step back from frontline management and oversee the research center.

Notably, all executives are expected to focus on CDO (Contract Development and Manufacturing Organization) with the dedication of sales personnel, aiming to restart antibiotic production through Hanmi’s chemical synthesis expertise.

A point of interest is that Lim Hae-ryong, General Manager of Beijing Hanmi Pharmaceutical, has been appointed head of the Domestic Business Division. General Manager Lim Hae-ryong is known as a key figure who, alongside President Lim Jong-yoon, built the current Beijing Hanmi Pharmaceutical and is recognized as a sales expert. He played a significant role in equipping Beijing Hanmi with sales expertise and raising its operating profit margin above 20%. If he returns to Hanmi Pharmaceutical, it is expected that he will transplant the DNA that grew Beijing Hanmi into Hanmi Pharmaceutical.

Above all, it is judged that his role is essential to raise Hanmi Pharmaceutical’s profit margin to the level of Beijing Hanmi. Earlier, President Lim Jong-yoon declared during the management rights dispute that he would elevate Hanmi Pharmaceutical Group to a market capitalization of 50 trillion won and a net profit of 1 trillion won. For this, improving the net profit of Hanmi Pharmaceutical, the core affiliate, must be the foundation. Last year, Hanmi Pharmaceutical’s operating profit margin was at the 11% level.

This is also why the current organizational restructuring is focused on aggressive sales. It reflects President Lim Jong-yoon’s determination to increase the operating profit margin through sales expansion. The strategy is interpreted as aiming to lead a structural improvement toward profit-centered operations through a sales-focused organizational restructuring.

Meanwhile, this organizational restructuring is expected to be carried out in line with President Lim Jong-yoon’s return as CEO of Hanmi Pharmaceutical.

This content was produced with the assistance of AI translation services.